StreetInsider.com News Articles

Form 144 ARVINAS, INC. Filed by: Berkowitz Noah

Tue, 04 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260804/26866473.html

Form 144 ARVINAS, INC. Filed by: Berkowitz Noah

Tue, 04 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260804/26866473.html

Form 10-Q ARVINAS, INC. For: Jun 30

Tue, 04 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260804/26866301.html

Form 10-Q ARVINAS, INC. For: Jun 30

Tue, 04 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260804/26866301.html

Wells Fargo Downgrades Arvinas Inc. (ARVN) to Equal Weight

Tue, 04 Aug 2026 13:11:21 -0400

Wells Fargo analyst Derek Archila downgraded Arvinas Inc. (NASDAQ: ARVN) from Overweight to Equal Weight.

For an analyst ratings summary and ratings history on Arvinas Inc. click here. For more ratings news on Arvinas Inc. click here.

Shares of Arvinas Inc. closed at $8.06 yesterday.

BTIG Reiterates Buy Rating on Arvinas Inc. (ARVN)

Tue, 04 Aug 2026 13:08:17 -0400

BTIG analyst Jeet Mukherjee reiterated a Buy rating and $18.00 price target on Arvinas Inc. (NASDAQ: ARVN).

The analyst commented: "ARVN reported earnings this morning, with 2Q26 marked by VEPPANU approval, formally closing the vepdegestrant chapter and redirecting focus to the wholly owned pipeline. The company also announced that ARV-806 dose escalation is complete, with data due 2H26 and mgmt actively seeking an out-license for any further development. From here, the story is about clinical execution across all programs, with 2H26 serving as the first real checkpoint with ARV-393 mono therapy data at a medical congress, ARV-102 biomarker updates at MDS

Arvinas, Inc. (ARVN) Tops Q2 EPS by 296c

Tue, 04 Aug 2026 07:28:32 -0400

Arvinas, Inc. (NASDAQ: ARVN) reported Q2 EPS of $2.58, $2.96 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $249.7 million versus the consensus estimate of $58.61 million.

For earnings history and earnings-related data on Arvinas, Inc. (ARVN) click here.

Form 8-K ARVINAS, INC. For: Aug 04

Tue, 04 Aug 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260804/26861388.html

Form 8-K ARVINAS, INC. For: Aug 04

Tue, 04 Aug 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260804/26861388.html

Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 04 Aug 2026 07:00:00 -0400

– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals –

– Anticipates sharing clinical data from three Phase 1 programs - ARV-393, ARV-102 and ARV-027 - over the next 12 months –

– Presented promising preclinical data for HPK1 degrader program (ARV-6723) demonstrating the potential to overcome immune checkpoint inhibitor resistance in solid tumors –

– Company to host conference call today at 8:00 a.m. ET –

NEW HAVEN, Conn., Aug. 04, 2026 (GLOBE NEWSWIRE) --

Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 04 Aug 2026 07:00:00 -0400

– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals –

– Anticipates sharing clinical data from three Phase 1 programs - ARV-393, ARV-102 and ARV-027 - over the next 12 months –

– Presented promising preclinical data for HPK1 degrader program (ARV-6723) demonstrating the potential to overcome immune checkpoint inhibitor resistance in solid tumors –

– Company to host conference call today at 8:00 a.m. ET –

NEW HAVEN, Conn., Aug. 04, 2026 (GLOBE NEWSWIRE) --

Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 04 Aug 2026 07:00:00 -0400

– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals –

– Anticipates sharing clinical data from three Phase 1 programs - ARV-393, ARV-102 and ARV-027 - over the next 12 months –

– Presented promising preclinical data for HPK1 degrader program (ARV-6723) demonstrating the potential to overcome immune checkpoint inhibitor resistance in solid tumors –

– Company to host conference call today at 8:00 a.m. ET –

NEW HAVEN, Conn., Aug. 04, 2026 (GLOBE NEWSWIRE) --

Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 04 Aug 2026 07:00:00 -0400

– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals –

– Anticipates sharing clinical data from three Phase 1 programs - ARV-393, ARV-102 and ARV-027 - over the next 12 months –

– Presented promising preclinical data for HPK1 degrader program (ARV-6723) demonstrating the potential to overcome immune checkpoint inhibitor resistance in solid tumors –

– Company to host conference call today at 8:00 a.m. ET –

NEW HAVEN, Conn., Aug. 04, 2026 (GLOBE NEWSWIRE) --

Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026

Tue, 28 Jul 2026 07:00:00 -0400

NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review second quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, August 4, 2026 at 8:00 a.m. ET.

The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of

Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026

Tue, 28 Jul 2026 07:00:00 -0400

Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026

Tue, 28 Jul 2026 07:00:00 -0400

Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026

Tue, 28 Jul 2026 07:00:00 -0400

Form 144 ARVINAS, INC. Filed by: Berkowitz Noah

Thu, 09 Jul 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260709/26753332.html

Form 144 ARVINAS, INC. Filed by: Berkowitz Noah

Thu, 09 Jul 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260709/26753332.html

Form 4 ARVINAS, INC. For: Jun 24 Filed by: Morrison Briggs